(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
31 October 2024 (31.10.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/226468 A3

(51) International Patent Classification:
C07K 16/30 (2006.01) *A61P 35/00* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2024/025780

(22) International Filing Date:
23 April 2024 (23.04.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/497,863 24 April 2023 (24.04.2023) US

(71) Applicant: **ELPIS PHARMACEUTICALS** [US/US]; 128 Spring Street, Lexington, Massachusetts 02421 (US).

(72) Inventors: **CHEN, Yan**; c/o Elpis Pharmaceuticals, 128 Spring Street, Lexington, Massachusetts 02421 (US). **ZHANG, Keming**; c/o Elpis Pharmaceuticals, 128 Spring Street, Lexington, Massachusetts 02421 (US). **ZHAO, Kehao**; c/o Elpis Pharmaceuticals, 128 Spring Street, Lexington, Massachusetts 02421 (US). **O'CALLAGHAN, Katie**; c/o Elpis Pharmaceuticals, 128 Spring Street, Lexington, Massachusetts 02421 (US). **JIANG, Ning**; c/o Elpis Pharmaceuticals, 128 Spring Street, Lexington, Massachusetts 02421 (US).

(74) Agent: **CHEN, Yahua**; c/o Mintz Levin, One Financial Center, Boston, Massachusetts 02111 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: ARMORED ANTI-B7H3 CAR-T CELLS AND USES THEREOF IN CANCER THERAPY




FIG. 2A

(57) Abstract: A chimeric antigen receptor (CAR) that binds B7 homolog 3 protein (B7H3) (anti-B7H3 CAR), which comprises: (a) an extracellular antigen binding moiety specific to human B7H3; (b) a co-stimulatory signaling domain; and (c) a cytoplasmic signal domain. Also provided herein are immune cells expressing the anti-B7H3 CAR, optionally in combination with an armor polypeptide, and uses thereof in cancer therapy.

[Continued on next page]

WO 2024/226468 A3

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

13 March 2025 (13.03.2025)